Q-omics provides the consensus-scored LMNB2 profile across patient tissues and cancer cell-line models. LMNB2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LMNB2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, LMNB2 protein abundance shows 30,757 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, HNSC, and LUAD as cancer lineages where LMNB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMNB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMNB2 survival associations across molecular data types. LMNB2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMNB2 RNA expression–survival associations across cancer types. High LMNB2 expression shows unfavorable associations in MESO, ACC, KIRC, KIRP, LIHC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LMNB2 RNA expression.
This table summarizes LMNB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LMNB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMNB2 shows higher tumor expression in HNSC, COAD, BLCA, KIRP, KIRC and STAD. The HNSC box plot shows higher LMNB2 RNA expression in tumor versus normal tissue (log2 FC = +1.776, t-test p < 0.001).
This table shows molecular features associated with LMNB2 in patient tissues and cancer cell lines. In patient samples, LMNB2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LMNB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
